Yervoy

(Ipilimumab)

Yervoy

Drug updated on 11/16/2023

Dosage FormInjection (intravenous; 5 mg/mL)
Drug ClassCytotoxic T-lymphocyte antigen 4 blocking antibodies
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single agent or in combination with nivolumab.
  • For the adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy.
  • For the treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma, as first-line treatment in combination with nivolumab.
  • For the treatment of adult and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, in combination with nivolumab.
  • For the treatment of adult patients with hepatocellular carcinoma who have been previously treated with sorafenib, in combination with nivolumab.
  • For the treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab.
  • For the treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy.
  • For the treatment of adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with nivolumab.
  • For the treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab.

Product Monograph / Prescribing Information

Document TitleYearSource
Yervoy (ipilimumab) Prescribing Information.2023Bristol-Myers Squibb Company, Princeton, NJ

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Efficacy of immune checkpoint inhibition in metastatic uveal melanoma: a systematic review and meta-analysis.2023Melanoma Research
Activity and safety of first-line treatments for advanced melanoma: a network meta-analysis.2023European Journal of Cancer
Efficacy and safety of the combined use of ipilimumab and nivolumab for melanoma patients with brain metastases: a systematic review and meta-analysis.2023Immunopharmacology and Imunotoxicology
Cost-effectiveness of first line nivolumab-ipilimumab combination therapy for advanced non-small cell lung cancer: a systematic review and methodological quality assessment.2023Frontiers in Health Sciences
Neoadjuvant treatment for stage III and IV cutaneous melanoma.2023The Cochrane Database of Systematic Reviews
First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis.2023The Cochrane Database of Systematic Reviews
Efficacy and Safety of Checkpoint Inhibitors in Clear Cell Renal Cell Carcinoma: A Systematic Review of Clinical Trials.2023Hematology/Oncology and Stem Cell Therapy
Treatment-related gastrointestinal adverse events of nivolumab plus ipilimumab in randomized clinical trials: a systematic review and meta-analysis.2023Future Oncology
Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817.2023Journal of Thoracic Oncology
Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis.2023Annals of Oncology
Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature review and network meta-analysis.2023Lung Cancer
Severe immune‑related adverse events of immune checkpoint inhibitors for advanced non‑small cell lung cancer: a network meta‑analysis of randomized clinical trials.2022Cancer Immunology, Immunotherapy
Efficacy and safety of first-line systemic therapy for metastatic renal cell carcinoma: a systematic review and network meta-analysis.2022European Urology Open Science
Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis.2022ESMO Open
Autoimmune retinopathy with associated anti-retinal antibodies as a potential immune-related adverse event associated with immunotherapy in patients with advanced cutaneous melanoma: case series and systematic review. 2022BMJ Open Ophthalmology
The efficacy and safety of combined ipilimumab and nivolumab versus ipilimumab in patients with stage III/IV unresectable melanoma: a systematic review and meta‑analysis.2022Journal of Cancer Research and Therapeutics
Best regimens for treating chemo-naïve incurable squamous non-small cell lung cancer with a programmed death-ligand 1 tumor proportion score of 1%–49%: a network meta-analysis.2022Thoracic Cancer
Low-dose ipilimumab in combination with nivolumab or pembrolizumab for the treatment of advanced melanoma.2022CADTH
A comprehensive evaluation of the safety of ipilimumab, nivolumab and their combination therapy: a systematic review and network meta-analysis.2022Journal of Oncology Pharmacy Practice
Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review.2022Therapeutic Advances in Medical Oncology
Immunotherapy-based combinations in the first-line treatment of metastatic renal cell carcinoma with sarcomatoid features: a systematic review and network meta-analysis.2022Current Opinion in Urology
Clinical Outcomes and Adverse Events after First-Line Treatment in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis.2022The Journal of Urology
Comparative risk of acute kidney injury among cancer patients treated with immune checkpoint inhibitors.2022Cancer communications
Risk of Adverse Events in Cancer Patients Receiving Nivolumab With Ipilimumab: A Meta-Analysis.2022Frontiers in Oncology
Clinical and pharmacoeconomic combined report: nivolumab (Opdivo) in combination with ipilimumab (Yervoy) for malignant pleural mesothelioma. 2021CADTH
Final clinical guidance report: nivolumab (Opdivo) with ipilimumab (Yervoy) for non-small cell lung cancer.2021CADTH
Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis.2021Therapeutic Advances in Urology
Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis.2021Cancer Cell International
The best regimens for chemo-naïve incurable non-squamous non-small cell lung cancer with a programmed death-ligand 1, tumor proportion score 1–49%: a network meta-analysis.2021Translational Lung Cancer Research
Comparative efficacy of treatments for brain metastases from non–small cell lung cancer without an EGFR-mutation/ALK-rearrangement: a systematic review and network meta-analysis.2021World Neurosurgery
Immune-related adverse events associated with immune checkpoint inhibitors for advanced non-small cell lung cancer: a network meta-analysis of randomized clinical trials.2021Frontiers in Pharmacology
Immune checkpoint inhibitor with or without radiotherapy in melanoma patients with brain metastases: a systematic review and meta-analysis.2021Korean Journal of Radiology
Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis.2021BMC Cancer
Immune checkpoint inhibitors for first-line treatment of advanced non-small-cell lung cancer: a systematic review and network meta-analysis.2021Thoracic Cancer
Chemotherapy in focus: a meta-analysis confronts immunotherapy in the treatment of advanced melanoma.2021Critical Reviews in Oncology/Hematology
A living, interactive systematic review and network meta-analysis of first-line treatment of metastatic renal cell carcinoma.2021European Urology
Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: systematic review and meta-analysis.2021PLoS One
Selection of optimal first-line immuno-related therapy based on specific pathological characteristics for patients with advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis.2021Therapeutic Advances in Medical Oncology
Systematic review and meta‑analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti‑PD‑1 progression: a systematic review and meta‑analysis.2021Clinical and Translational Oncology
Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without bevacizumab for people with advanced non‐small cell lung cancer.2021The Cochrane Database of Systematic Reviews
Single Technology Appraisal Nivolumab with ipilimumab for untreated metastatic renal cell carcinoma [ID1182] Committee Papers.2021NICE
Adverse events of systemic immune-based combination therapies in the first-line treatment of patients with metastatic renal cell carcinoma: systematic review and network meta-analysis.2021Current Opinion in Urology
First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.2021European Urology Oncology
The efficacy and safety of Nivolumab combined with Ipilimumab in the immunotherapy of cancer: a meta-analysis.2021Immunopharmacology and Immunotoxicology
Economic evaluation of systemic treatments for advanced melanoma: a systematic review.2020Value in Health
The risk ratio of immune-related colitis, hepatitis, and pancreatitis in patients with solid tumors caused by PD-1/PD-L1 inhibitors: a systematic review and meta-analysis.2020Frontiers in Oncology
Immune checkpoint inhibitors and immune-related adverse events in patients with advanced melanoma.2020JAMA Network Open
First-line treatments for advanced renal cell carcinoma with immune checkpoint inhibitors: systematic review, network meta-analysis and cost-effectiveness analysis.2020Therapeutic Advances in Medical Oncology
Immune checkpoint inhibitors in advanced or metastatic mucosal melanoma: a systematic review.2020Therapeutic Advances in Medical Oncology
Targeted therapy for metastatic renal cell carcinoma.2020The Cochrane Database of Systematic Reviews
Immune checkpoint inhibitors in advanced acral melanoma: a systematic review.2020Frontiers in Oncology
Nivolumab plus Ipilimumab versus Existing Immunotherapies in Patients with PD-L1-Positive Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.2020Cancers
Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis.2020Frontiers in Oncology
Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis.2020Expert Opinion on Drug Safety
Immune Checkpoint Inhibitors for Patients Aged ≥ 75 Years with Advanced Cancer in First- and Second-Line Settings: A Meta-Analysis.2020Drugs and Aging
Comparative Efficacy of First-Line Immune-Based Combination Therapies in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis.2020Cancers
Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: a Bayesian network analysis. 2019EBioMedicine
The differences in the safety and tolerability of immune checkpoint inhibitors as treatment for non–small cell lung cancer and melanoma: network meta-analysis and systematic review.2019Frontiers in Pharmacology
Immunotherapy for metastatic renal cell carcinoma: a systematic review.2019Journal or Evidence-Based Medicine
Final clinical guidance report: nivolumab (Opdivo) with ipilimumab (Yervoy) for renal cell carcinoma.2018CADTH
Efficacy and safety of ipilimumab plus chemotherapy for advanced lung cancer: a systematic review and meta-analysis. 2018Journal of Cancer
Risk of immune-related pancreatitis in patients with solid tumors treated with immune checkpoint inhibitors: systematic assessment with meta-analysis.2018Journal of Immunology Research
Nivolumab monotherapy or in combination with ipilimumab for metastatic melanoma: systematic review and meta-analysis of randomized-controlled trials.2018Melanoma Research
Clinical and molecular characteristics associated with survival in advanced melanoma treated with checkpoint inhibitors.2018Journal of Oncology
Gastrointestinal adverse events with combination of checkpoint inhibitors in advanced melanoma: a systematic review.2018Melanoma Management

Clinical Practice Guidelines

Document TitleYearSource
Esophageal and esophagogastric junction cancers, version 2.2023, NCCN clinical practice guidelines in oncology.2023Official Journal of the National Comprehensive Cancer Network
The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma.2023European Eurology
The Society for Immunotherapy of Cancer clinical practice guideline on immunotherapy for hepatocellular carcinoma.2023HepatoBiliary Surgery and Nutrition
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.2023Journal for ImmunoTherapy of Cancer
Systemic Therapy for Melanoma: ASCO Guideline Update.2023Journal of Clinical Oncology
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.2023Journal of Clinical Oncology
Systemic therapy in metastatic renal cell carcinoma (mRCC): an evidence‑based recommendation of the German interdisciplinary RCC guidelines group.2022World Journal of Urology
AGA clinical practice guideline on systemic therapy for hepatocellular carcinoma.2022Gastroenterology
ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. 2021Annals of Oncology
SEOM clinical guideline for the management of cutaneous melanoma (2020).2021Clinical and Translational Oncology
Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update.2020Clinical & Translational Oncology
Systemic adjuvant therapy for adult patients at high risk for recurrent cutaneous or mucosal melanoma: an Ontario Health (Cancer Care Ontario) clinical practice guideline.2020Current Oncology
Systemic therapy for melanoma: ASCO guideline.2020Journal of Clinical Oncology
Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.2019Annals of Oncology
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC).2019Journal of Immunotherapy and Cancer
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.2018Journal for the ImmunoTherapy of Cancer